Relapsed/Refractory Myelofibrosis clinical trials at UC Cancer
1 research study open to eligible people
open to eligible people ages 18 years and up
This is a Phase 1 cohort, dose-escalation, dose-expansion study of PRT543 in patients with advanced cancers who have exhausted available treatment options. The purpose of this study is to define a safe dose and schedule to be used in subsequent development of PRT543.